{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:12:29Z","timestamp":1782915149589,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic Kidney Disease (CKD) complications, like cardiovascular complications, are one of the leading causes of mortality. Managing the biochemical profile is essential in slowing the progression of CKD and its associated consequences. This study aimed to assess the effect of cinacalcet add-on therapy on clinical outcomes in patients with End-Stage Renal Disease (ESRD) on Hemodialysis (HD) who developed Secondary Hyperparathyroidism and are receiving hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A mixed retrospective-prospective cohort multicenter study was conducted in three hospitals in Saudi Arabia between December 1st, 2019, and January 31st, 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and seventy-four subjects were analyzed; the incidence of the cardiovascular events and the first cardiovascular events in patients on cinacalcet was significantly decreased compared to the patients on the conventional therapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02 &amp; 0.005,\n                      <jats:italic>respectively<\/jats:italic>\n                      ). The incidence of coronary artery diseases was significantly decreased by 61% in the patients on cinacalcet (\n                      <jats:italic>HR\u2009=\u20090.39<\/jats:italic>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Patients on Cinacalcet were 69% less in all-cause first hospitalization hazard ratio;\n                      <jats:italic>HR<\/jats:italic>\n                      \u2009=\u2009\n                      <jats:italic>0.31<\/jats:italic>\n                      ,\n                      <jats:italic>95% CI: 0.16\u20130.63<\/jats:italic>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001. There was no significant reduction in the risk of all-cause and cardiovascular mortality in the patients on Cinacalcet (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06 &amp; 0.12,\n                      <jats:italic>respectively<\/jats:italic>\n                      ), but patients with Hypertension and \u201cDiabetes Mellitus &amp; Hypertension\u201d etiology had a lower mortality\n                      <jats:italic>HR<\/jats:italic>\n                      (Hypertension:\n                      <jats:italic>HR\u2009=\u20090.46<\/jats:italic>\n                      ,\n                      <jats:italic>95% CI\u2009=\u20090.21-1.00<\/jats:italic>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05; \u201cDiabetes Mellitus &amp; Hypertension\u201d:\n                      <jats:italic>HR<\/jats:italic>\n                      \u2009=\u2009\n                      <jats:italic>0.42<\/jats:italic>\n                      ,\n                      <jats:italic>95% CI\u2009=\u20090.2-1.00<\/jats:italic>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). There was no significant difference in the frequency of incidence of bone fractures between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.26).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cinacalcet is superior in decreasing the frequency of cardiovascular events. However, it is not effective in reducing the risk of all-cause and cardiovascular mortality, except in patients with \u201cHypertension\u201d and \u201cDiabetes Mellitus &amp; Hypertension\u201d etiology, and it might offer a somewhat protective trend in males and older patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04455-y","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:32:15Z","timestamp":1758879135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world evaluation of cinacalcet on hard outcomes in hemodialysis patients in Saudi Arabia"],"prefix":"10.1186","volume":"26","author":[{"given":"Riad Mohammed","family":"Abdelrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmi Mohamed Ali","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz Ahmed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Hussien","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Adam","family":"Arbab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltieb Omer","family":"Abuelgasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif Amin","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Altrefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda Babikir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"4455_CR1","doi-asserted-by":"publisher","unstructured":"Levin A, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. Jan. 2013;3(1):1\u2013150. https:\/\/doi.org\/10.1038\/kisup.2012.73\/asset\/17b771fc-c316-4412-a27e-17ed1f7afb8a\/main.assets\/fx1.gif.","DOI":"10.1038\/kisup.2012.73\/asset\/17b771fc-c316-4412-a27e-17ed1f7afb8a\/main.assets\/fx1.gif"},{"key":"4455_CR2","doi-asserted-by":"publisher","unstructured":"KDIGO KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. 2024. https:\/\/doi.org\/10.1016\/S0085-2538(24)00110-8.","DOI":"10.1016\/S0085-2538(24)00110-8"},{"key":"4455_CR3","doi-asserted-by":"publisher","unstructured":"Hu L, et al. Mineral bone disorders in kidney disease patients: the ever-current topic. Int J Mol Sci. Oct. 2022;23(20):12223. https:\/\/doi.org\/10.3390\/ijms232012223.","DOI":"10.3390\/ijms232012223"},{"key":"4455_CR4","doi-asserted-by":"publisher","unstructured":"Alshehri MA, et al. Prevalence of chronic kidney disease in Saudi Arabia: an epidemiological population-based study, BMC Nephrol. 2025 Dec;26(1):1\u201311. https:\/\/doi.org\/10.1186\/s12882-025-03954-2\/figures\/2.","DOI":"10.1186\/s12882-025-03954-2\/figures\/2"},{"key":"4455_CR5","doi-asserted-by":"publisher","unstructured":"Kim HJ, et al. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol. 2013 May ;14:112. https:\/\/doi.org\/10.1186\/1471-2369-14-112.","DOI":"10.1186\/1471-2369-14-112"},{"key":"4455_CR6","unstructured":"Dr\u00fceke TB. Hyperparathyroidism in chronic kidney disease, Endotext. 2025 Feb. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK278975\/."},{"key":"4455_CR7","unstructured":"KDIGO. Guidelines \u2013 KDIGO. [Online]. Available: https:\/\/kdigo.org\/guidelines\/. Accessed: Aug. 18, 2025."},{"key":"4455_CR8","doi-asserted-by":"publisher","first-page":"419524","DOI":"10.4061\/2011\/419524","volume":"2011","author":"L Gravellone","year":"2011","unstructured":"Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol. 2011;2011:419524. https:\/\/doi.org\/10.4061\/2011\/419524.","journal-title":"Int J Nephrol"},{"key":"4455_CR9","unstructured":"KDIGO. CKD-Mineral and Bone Disorder (CKD-MBD) \u2013 KDIGO. [Online]. Available: https:\/\/kdigo.org\/guidelines\/ckd-mbd\/. Accessed: Aug. 18, 2025."},{"key":"4455_CR10","doi-asserted-by":"publisher","unstructured":"Ketteler M, et al. Executive summary of the 2017 KDIGO chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 2017;92(1). https:\/\/doi.org\/10.1016\/j.kint.2017.04.006.","DOI":"10.1016\/j.kint.2017.04.006"},{"key":"4455_CR11","doi-asserted-by":"publisher","unstructured":"Fishbane S, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results, Clin. J. Am. Soc. Nephrol. 2008 Nov;3(6):1718\u20131725. https:\/\/doi.org\/10.2215\/CJN.01040308.","DOI":"10.2215\/CJN.01040308"},{"issue":"4","key":"4455_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/1319-2442.388184","volume":"33","author":"M Al-Homrany","year":"2022","unstructured":"Al-Homrany M, Saeed M, Ali F, Al-Ghamdi S, Mousa D, Alharbi A. The effectiveness of alternate-day Cinacalcet therapy for secondary hyperparathyroidism in noncompliant Hemodialysis patients. Saudi J Kidney Dis Transpl. 2022;33(4):503\u20138. https:\/\/doi.org\/10.4103\/1319-2442.388184.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"4455_CR13","doi-asserted-by":"publisher","unstructured":"Susantitaphong P, et al. The effectiveness of cinacalcet: a randomized, open-label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail. 2019 Jan;41(1):326\u201333. https:\/\/doi.org\/10.1080\/0886022X.2018.1562356.","DOI":"10.1080\/0886022X.2018.1562356"},{"key":"4455_CR14","doi-asserted-by":"publisher","unstructured":"Mima A. Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease. Adv Ther. 2021 May;38(5):2201\u201312. https:\/\/doi.org\/10.1007\/S12325-021-01735-5\/METRICS.","DOI":"10.1007\/S12325-021-01735-5\/METRICS"},{"key":"4455_CR15","doi-asserted-by":"publisher","unstructured":"Mima A, Nomura A, Fujii T. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: a narrative review. Biomed Pharmacother. 2023 Sep;165:115032. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.115032.","DOI":"10.1016\/J.BIOPHA.2023.115032"},{"key":"4455_CR16","doi-asserted-by":"publisher","unstructured":"Mima A. A narrative review of diabetic kidney disease: Previous and current evidence-based therapeutic approaches, Adv. Ther. 2022 Aug;39(8):3488\u20133500. https:\/\/doi.org\/10.1007\/S12325-022-02223-0\/METRICS.","DOI":"10.1007\/S12325-022-02223-0\/METRICS"},{"key":"4455_CR17","doi-asserted-by":"publisher","unstructured":"Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease, J. Ren. Nutr. 2006 Jul;16(3):253\u2013258. https:\/\/doi.org\/10.1053\/j.jrn.2006.04.010.","DOI":"10.1053\/j.jrn.2006.04.010"},{"issue":"1","key":"4455_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-015-0174-6","volume":"16","author":"BD Reams","year":"2015","unstructured":"Reams BD, et al. Dynamics of Cinacalcet use and biochemical control in Hemodialysis patients: A retrospective new-user cohort design. BMC Nephrol. 2015;16(1):1\u201312. https:\/\/doi.org\/10.1186\/s12882-015-0174-6.","journal-title":"BMC Nephrol"},{"key":"4455_CR19","doi-asserted-by":"publisher","unstructured":"Block GA, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients, Kidney Int. 2010 Sep;78(6):578\u2013589. https:\/\/doi.org\/10.1038\/ki.2010.167.","DOI":"10.1038\/ki.2010.167"},{"key":"4455_CR20","doi-asserted-by":"publisher","unstructured":"Zhang Q, et al. Effects and safety of calcimimetics in end-stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS ONE. 2012 Oct;7(10):e48070. https:\/\/doi.org\/10.1371\/journal.pone.0048070.","DOI":"10.1371\/journal.pone.0048070"},{"key":"4455_CR21","doi-asserted-by":"publisher","unstructured":"Parfrey PS, et al. Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis, Clin. J. Am. Soc. Nephrol. 2016 Mar;11(3):539\u2013546. https:\/\/doi.org\/10.2215\/CJN.06370615.","DOI":"10.2215\/CJN.06370615"},{"key":"4455_CR22","doi-asserted-by":"publisher","unstructured":"Evans M, et al. Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Sci Rep. 2018 Dec;8(1). https:\/\/doi.org\/10.1038\/s41598-018-20552-5.","DOI":"10.1038\/s41598-018-20552-5"},{"key":"4455_CR23","doi-asserted-by":"publisher","unstructured":"Komaba H, Fukagawa M. Cinacalcet and clinical outcomes in dialysis, Semin. Dial. 2015 Nov;28(6):594\u2013603. https:\/\/doi.org\/10.1111\/sdi.12413.","DOI":"10.1111\/sdi.12413"},{"key":"4455_CR24","doi-asserted-by":"publisher","unstructured":"Sin HY. Prospective cohort study: cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital, J. Clin. Pharm. Ther. 2017 Oct;42(5):607\u2013614. https:\/\/doi.org\/10.1111\/jcpt.12565.","DOI":"10.1111\/jcpt.12565"},{"key":"4455_CR25","doi-asserted-by":"publisher","unstructured":"Li X, Ding W, Zhang H. Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review. 2023:1\u201316, https:\/\/doi.org\/10.3389\/fendo.2023.1146955","DOI":"10.3389\/fendo.2023.1146955"},{"key":"4455_CR26","doi-asserted-by":"publisher","unstructured":"Moe SM, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015 Jul;132(1):27\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013876.","DOI":"10.1161\/CIRCULATIONAHA.114.013876"},{"key":"4455_CR27","doi-asserted-by":"publisher","unstructured":"Lozano-Ortega G, et al. Effects of calcimimetics on long-term outcomes in Dialysis patients: literature review and bayesian meta-analysis. J Comp Eff Res. 2018 Jul;7(7):693\u2013707. https:\/\/doi.org\/10.2217\/cer-2018-0015.","DOI":"10.2217\/cer-2018-0015"},{"key":"4455_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz021","author":"J Rottembourg","year":"2019","unstructured":"Rottembourg J, et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with Cinacalcet in real-world clinical practice: mimosa study. Clin Kidney J Mar. 2019. https:\/\/doi.org\/10.1093\/ckj\/sfz021.","journal-title":"Clin Kidney J Mar"},{"key":"4455_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001436","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, et al. Cinacalcet in patients with chronic kidney disease:factor-23 cumulative meta-analysis of randomized controlled trials. PLoS Med Apr. 2013. https:\/\/doi.org\/10.1371\/journal.pmed.1001436.","journal-title":"PLoS Med Apr"},{"key":"4455_CR30","doi-asserted-by":"publisher","unstructured":"Wheeler DC, et al. Effects of Cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EVOLVE trial. J Am Heart Assoc. 2014;3(6). https:\/\/doi.org\/10.1161\/JAHA.114.001363.","DOI":"10.1161\/JAHA.114.001363"},{"key":"4455_CR31","doi-asserted-by":"publisher","unstructured":"Yuan F, Chen X, Wang C, Li Z, Liu H. Effect of cinacalcet combined with calcitriol on the clinical outcome and bone metabolism in patients on hemodialysis with severe secondary hyperparathyroidism, Blood Purif. 2018 Apr;45(1\u20133):73\u201378. https:\/\/doi.org\/10.1159\/000484435.","DOI":"10.1159\/000484435"},{"key":"4455_CR32","doi-asserted-by":"publisher","unstructured":"Friedl C, et al. Mortality in dialysis patients with cinacalcet use: a large observational registry study. Eur J Intern Med. 2017 Jul;42:89\u201395. https:\/\/doi.org\/10.1016\/j.ejim.2017.05.002.","DOI":"10.1016\/j.ejim.2017.05.002"},{"key":"4455_CR33","doi-asserted-by":"crossref","unstructured":"Al-Sayyari AA, Shaheen FA. End-stage chronic kidney disease in Saudi Arabia: A rapidly changing scene, Saudi Med. J. 2011;32(4):339\u2013346. [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21483990.","DOI":"10.15537\/1658-3175.5267"},{"key":"4455_CR34","doi-asserted-by":"publisher","unstructured":"Al-Hwiesh A, Alsaloom A, Gupta KL. Efficacy of Cinacalcet for the treatment of secondary hyperparathyroidism in CKD patients on peritoneal or hemodialysis: the middle-east experience. J Nephrol Ther. 2012;2(1). https:\/\/doi.org\/10.4172\/2161-0959.1000113.","DOI":"10.4172\/2161-0959.1000113"},{"key":"4455_CR35","doi-asserted-by":"crossref","unstructured":"Bashir SO, Omer HA, Aamer MA, Somialy R, Morsy MD, Omar Bashir S. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients, 2015. [Online]. Available: http:\/\/www.wma.net\/e\/policy\/. Accessed: Jul. 24, 2019.","DOI":"10.4103\/1319-2442.168583"},{"key":"4455_CR36","doi-asserted-by":"publisher","unstructured":"Alharthi AA, Kamal NM, Abukhatwah MW, Sherief LM. Cinacalcet in pediatric and adolescent chronic kidney disease. Med (Baltim). 2015 Jan;94(2):e401. https:\/\/doi.org\/10.1097\/MD.0000000000000401.","DOI":"10.1097\/MD.0000000000000401"},{"key":"4455_CR37","unstructured":"Wiley. Medical statistics at a glance, 3rd Edition. [Online]. Available: https:\/\/www.wiley.com\/en-sd\/Medical+Statistics+at+a+Glance,+3rd+Edition-p-9781118782446. Accessed: Jul. 29, 2020."},{"key":"4455_CR38","doi-asserted-by":"publisher","unstructured":"Herzog CA et al. Cardiovascular disease in chronic kidney disease: a clinical update from kidney disease: improving global outcomes (KDIGO). 2011, https:\/\/doi.org\/10.1038\/ki.2011.223.","DOI":"10.1038\/ki.2011.223"},{"key":"4455_CR39","doi-asserted-by":"publisher","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance Hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208\u201318. https:\/\/doi.org\/10.1097\/01.ASN.0000133041.27682.A2.","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"4455_CR40","doi-asserted-by":"publisher","unstructured":"Zoccali C. Cardiovascular complications in chronic kidney disease: a review from the European renal and Cardiovascular medicine working group of the European renal association, Cardiovasc. Res. 2023 Aug;119(11):2017\u20132032. https:\/\/doi.org\/10.1093\/cvr\/cvad083.","DOI":"10.1093\/cvr\/cvad083"},{"key":"4455_CR41","doi-asserted-by":"publisher","unstructured":"Sun Y, Tian B, Sheng Z, Wan P, Xu T, Yao L. Efficacy and safety of Cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis. BMC Nephrol. 2020 Jul;21(1). https:\/\/doi.org\/10.1186\/s12882-019-1639-9.","DOI":"10.1186\/s12882-019-1639-9"},{"key":"4455_CR42","doi-asserted-by":"publisher","unstructured":"Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism, Kidney Int. 2005 Oct;68(4):1793\u20131800. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00596.x.","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"4455_CR43","doi-asserted-by":"publisher","unstructured":"Asada S, et al. Effectiveness of Cinacalcet treatment for secondary hyperparathyroidism on hospitalization: results from the MBD-5D study. PLoS ONE. 2019 May;14(5). https:\/\/doi.org\/10.1371\/journal.pone.0216399.","DOI":"10.1371\/journal.pone.0216399"},{"key":"4455_CR44","doi-asserted-by":"publisher","unstructured":"Pereira L, Meng C, Marques D, Fraz\u00e3o JM. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J. 2018 Feb;11(1):80\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfx125.","DOI":"10.1093\/ckj\/sfx125"},{"key":"4455_CR45","doi-asserted-by":"publisher","unstructured":"Engl N, Med. J. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, N. Engl. J. Med. 2012 Dec;367(26):2482\u20132494. https:\/\/doi.org\/10.1056\/nejmoa1205624.","DOI":"10.1056\/nejmoa1205624"},{"key":"4455_CR46","doi-asserted-by":"publisher","unstructured":"Parfrey PS, et al. The effects of Cinacalcet in older and younger patients on hemodialysis: the evaluation of Cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015 Jan;10(5):791\u20139. https:\/\/doi.org\/10.2215\/CJN.07730814.","DOI":"10.2215\/CJN.07730814"},{"key":"4455_CR47","doi-asserted-by":"publisher","unstructured":"Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States, J. Am. Soc. Nephrol. 2006 Nov;17(11):3223\u20133232. https:\/\/doi.org\/10.1681\/ASN.2005111194.","DOI":"10.1681\/ASN.2005111194"},{"key":"4455_CR48","doi-asserted-by":"publisher","unstructured":"Maravic M, Ostertag A, Torres PU, Cohen-Solal M. Incidence and risk factors for hip fractures in Dialysis patients. Osteoporos Int. 2014 Jan;25(1):159\u201365. https:\/\/doi.org\/10.1007\/s00198-013-2435-1.","DOI":"10.1007\/s00198-013-2435-1"},{"key":"4455_CR49","doi-asserted-by":"publisher","unstructured":"Moe SM et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial, J. Am. Soc. Nephrol. 2015 Jun;26(6):1466\u20131475. https:\/\/doi.org\/10.1681\/ASN.2014040414.","DOI":"10.1681\/ASN.2014040414"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04455-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:39:55Z","timestamp":1781609995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04455-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4455"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04455-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The \u201cScientific Research Unit\u201d at Mohammed Al-Mana College for Medical Sciences, Al-Khobar, Saudi Arabia, had approved this study, with a waiver of the requirement for obtaining written informed consent due to its mainly retrospective nature. The wavering of written informed consent was granted for both the retrospective and prospective components, as the study involved no interventions, posed minimal risk to participants, and relied solely on routinely collected clinical data. All data were anonymized prior to analysis to ensure confidentiality (Approval Reference number: SR\/RP\/13, Date of Approval: 28\/2\/2019). The investigators asserts that all procedures contributing to this study comply with the Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"528"}}